Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

por Fasanmade, Adedigbo A., Adedokun, Omoniyi J., Ford, Joyce, Hernandez, Danika, Johanns, Jewel, Hu, Chuanpu, Davis, Hugh M., Zhou, Honghui
Publicado 2009

Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn’s Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study

por Rosh, Joel R, Turner, Dan, Griffiths, Anne, Cohen, Stanley A, Jacobstein, Douglas, Adedokun, Omoniyi J, Padgett, Lakshmi, Terry, Natalie A, O’Brien, Christopher, Hyams, Jeffrey S
Publicado 2021

Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials

por Xu, Steven X., Samtani, Mahesh N., Russu, Alberto, Adedokun, Omoniyi J., Lu, Ming, Ito, Kaori, Corrigan, Brian, Raje, Sangeeta, Brashear, H. Robert, Styren, Scot, Hu, Chuanpu
Publicado 2015

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab

por Samtani, Mahesh N., Xu, Steven X., Russu, Alberto, Adedokun, Omoniyi J., Lu, Ming, Ito, Kaori, Corrigan, Brian, Raje, Sangeeta, Brashear, H. Robert, Styren, Scot, Hu, Chuanpu
Publicado 2015

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Mai...

por Adedokun, Omoniyi J., Xu, Zhenhua, Marano, Colleen W., Strauss, Richard, Zhang, Hongyan, Johanns, Jewel, Zhou, Honghui, Davis, Hugh M., Reinisch, Walter, Feagan, Brian G., Rutgeerts, Paul, Sandborn, William J.
Publicado 2017

Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results

por Hyams, Jeffrey S, O’Brien, Christopher D, Padgett, Lakshmi, Rosh, Joel R, Turner, Dan, Veereman, Genevieve, Griffiths, Anne M, Heyman, Melvin B, Wahbeh, Ghassan, Adedokun, Omoniyi J, Strauss, Richard S, Lynch, John P, Chan, Daphne
Publicado 2020